Effects of anti-RBC monoclonal antibody therapy on the time course of MWReg30-mediated thrombocytopenia. MWReg30 was administered to mice via intraperitoneal infusion (0.99 μg/d × 7 days), and TER119 was given by intravenous bolus injection at 96 hours. Platelet counts were obtained using a Cell-Dyn 1700 multiparameter hematology analyzer. Symbols represent the sham control group (•) and animals treated with saline (▾), 5 μg/mouse (▪), 15 μg/mouse (♦), 25 μg/mouse (▴), or 50 μg/mouse (+). Error bars represent the standard deviation associated with the platelet counts. TER119 attenuated MWReg30-mediated thrombocytopenia in a dose-dependent manner. Treatment differences were statistically significant (P < .001).